Thomas Bures
Direttore Finanziario/CFO presso PIERIS PHARMACEUTICALS, INC.
Patrimonio netto: 2 796 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Thomas Bures
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 23 | |
| Public Company | Biotechnology | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Thomas Bures tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| CELGENE | Biotechnology | Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Chief Tech/Sci/R&D Officer | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
Citigroup Alternative Investments LLC
 Citigroup Alternative Investments LLC Investment ManagersFinance Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc. | Investment Managers | Portfolio Manager-Equities | |
| SANOFI | Biotechnology | Corporate Officer/Principal Chief Operating Officer | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Lombard Odier Asset Management (USA) Corp.
 Lombard Odier Asset Management (USA) Corp. Investment ManagersFinance Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors. | Investment Managers | Portfolio Manager-Equities | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree | |
| MORPHOSYS AG | Biotechnology | General Counsel Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree | |
| Grove City College | College/University | Undergraduate Degree | |
| University of Toronto | College/University | Doctorate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| University of Nice Sophia Antipolis | College/University | Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
| European Organisation for Research & Treatment of Cancer | Director/Board Member | ||
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Danforth Advisors LLC
 Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Investment Managers | Corporate Officer/Principal Director/Board Member | |
| George Washington University Law School | College/University | Graduate Degree | |
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
| FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
| Isabella Stewart Gardner Museum | Consultant / Advisor | ||
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Biotechnology | Director/Board Member | |
| PRIME MEDICINE, INC. | Biotechnology | Director of Finance/CFO | |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Pharmaceuticals: Major | Director/Board Member | |
| DISC MEDICINE, INC. | Biotechnology | Director/Board Member | |
Judo Bio, Inc.
 Judo Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Judo Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA. The company was founded in 2021 by Chelsea Place Johnson. | Miscellaneous Commercial Services | Director/Board Member | |
| Morphic Rock LLC | Corporate Officer/Principal | ||
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 36 |
| Francia | 6 |
| Germania | 4 |
| Canada | 3 |
| Islanda | 2 |
Settori
| Health Technology | 26 |
| Finance | 12 |
| Consumer Services | 10 |
| Commercial Services | 3 |
Posizioni
| Director/Board Member | 147 |
| Corporate Officer/Principal | 71 |
| Independent Dir/Board Member | 46 |
| Chief Tech/Sci/R&D Officer | 35 |
| Chairman | 26 |
Contatti più connessi
| Insiders | |
|---|---|
| Kevin Bitterman | 36 |
| Stephen Hoffman | 33 |
| James Geraghty | 25 |
| Peter Kiener | 25 |
| Jean Bizzari | 24 |
| Julian Adams | 22 |
| Howard Mayer | 16 |
| Michael Richman | 16 |
| Matthew Sherman | 16 |
| Steven Prelack | 15 |
| Allan Reine | 14 |
| Lance Thibault | 11 |
| Christopher Kiritsy | 10 |
| John Bishop | 10 |
| Ann J. Barbier | 9 |
- Borsa valori
- Insiders
- Thomas Bures
- Connessioni Società